Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study

Monika Joshi,Sheldon L. Holder,Junjia Zhu,Hong Zheng, Shraddha Komanduri,Joshua Warrick,Hesham Yasin,Rohan Garje,Bei Jia,Joseph J. Drabick,David J. DeGraff,Yousef Zakharia

European Urology Focus（2022）

引用 1|浏览12

暂无评分

摘要

The combination of avelumab and low-dose eribulin showed encouraging safety and efficacy signals in a small cohort of patients with metastatic urothelial cancer. Responses were also observed among patients with FGFR abnormalities. This combination should be evaluated further in a larger clinical trial.

查看译文

关键词

Avelumab,Eribulin,Urothelial carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要